[1. Petrović D. Akutno oštećenje bubrega: etiologija, dijagnostika i lečenje. Medicinska Istraživanja. 2011;45(3):7-13.]Search in Google Scholar
[2. Said A, Haddad RY, Stein R, Lerma EV. Thrombotic thrombocytopenic purpura. Dis Mon. 2014;60(10):500-4.10.1016/j.disamonth.2014.08.00525278278]Search in Google Scholar
[3. Crawley JT, Scully MA. Thrombotic thrombocytopenic purpura: basic pathophysiology and therapeutic strategies. Hematology Am Soc Hematol Educ Program. 2013;2013(1):292-9.10.1182/asheducation-2013.1.29224319194]Search in Google Scholar
[4. Barbour T, Johnson S, Cohney S, Hughes P. Thrombotic microangiopathy and associated renal disorders. Nephrol Dial Transplant. 2012;27(7):2673-85.10.1093/ndt/gfs279339806722802583]Search in Google Scholar
[5. Kremer Hovinga JA, Lammle B. Role of ADAMTS13 in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program. 2012;2012(1):610-6.10.1182/asheducation.V2012.1.610.3798654]Search in Google Scholar
[6. Giblin JP, Hewlett LJ, Hannah MJ. Basal secretion of von Willebrand factor from human endothelial cells. Blood. 2008;112(4):957-964.10.1182/blood-2007-12-13074018344423]Search in Google Scholar
[7. Springer TA. Biology and physics of von Willebrand factor concatamers. J Thromb Haemost. 2011;9(Suppl 1):130-143.10.1111/j.1538-7836.2011.04320.x411735021781248]Search in Google Scholar
[8. Zhou YF, Eng ET, Zhu J, et al. Sequence and structure relationships within von Willebrand factor. Blood. 2012;120(2):449-458.10.1182/blood-2012-01-405134339876522490677]Search in Google Scholar
[9. Zhang X, Halvorsen K, Zhang CZ, et al. Mechanoenzymatic cleavage of the ultralarge vascular protein von Willebrand factor. Science. 2009;324(5932):1330-1334.10.1126/science.1170905275318919498171]Search in Google Scholar
[10. Siedlecki CA, Lestini BJ, Kottke-Marchant KK, et al. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. Blood. 1996;88(8):2939-2950.10.1182/blood.V88.8.2939.bloodjournal8882939]Search in Google Scholar
[11. Bianchi V, Robles R, Alberio L, et al. Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood. 2002;100:710-13.10.1182/blood-2002-02-034412091372]Search in Google Scholar
[12. Scully M, Yarranton H, Liesner R, et al. Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features. Br J Haematol. 2008;142(5):819-826.10.1111/j.1365-2141.2008.07276.x18637802]Search in Google Scholar
[13. Ferrari S, Mudde GC, Rieger M, et al. IgG subclass distribution of anti-ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost. 2009;7(10):1703-1710.10.1111/j.1538-7836.2009.03568.x19682238]Search in Google Scholar
[14. Ferrari S, Scheiflinger F, Rieger M, et al. Prognostic value of 614 American Society of Hematology anti- ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. Blood. 2007;109(7):2815-2822.10.1182/blood-2006-02-00606417164349]Search in Google Scholar
[15. Hunt BJ, Lämmle B, Nevard CH, et al. von Willebrand factor-cleaving protease in childhood diarrhoeaassociated haemolytic uraemic syndrome. Thromb Haemost. 2001;85(6):975-978.10.1055/s-0037-1615949]Search in Google Scholar
[16. Terrell DR, Williams LA, Vesely SK, et al. The incidence of thrombotic thrombocytopenic purpurahemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J.Thromb.Haemost 2005;3(7):1432-1436.10.1111/j.1538-7836.2005.01436.x15978100]Search in Google Scholar
[17. Tsai HM. The kidney in thrombotic thrombocytopenic purpura. Minerva Med. 2007;98(6):731-47.]Search in Google Scholar
[18. Bennett CL, Davidson CJ, Raisch DW, et al. Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention. Arch.Intern.Med 1999;159(21):2524-2528.]Search in Google Scholar
[19. Tsai HM, Rice L, Sarode R, et al. Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidineassociated thrombotic thrombocytopenic purpura. Ann Intern.Med 2000;132(10):794-799.]Search in Google Scholar
[20. Lattuada A, Rossi E, Calzarossa C, et al. Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome. Haematologica 2003;88(9):1029-1034.]Search in Google Scholar
[21. Scully M, Yarranton H, Liesner R, et al. Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features. Br J Haematol 2008;142(5):819-826.10.1111/j.1365-2141.2008.07276.x]Search in Google Scholar
[22. Jiang Y, McIntosh JJ, Reese JA, et al. Pregnancy outcomes following recovery from acquired thrombotic thrombocytopenic purpura. Blood. 2014;123(11):1674-80.10.1182/blood-2013-11-538900395404924398329]Search in Google Scholar
[23. Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001;413(6855):488-494.10.1038/3509700811586351]Search in Google Scholar
[24. Schneppenheim R, Kremer Hovinga JA, Becker T, et al. A common origin of the 4143insA ADAMTS13 mutation. Thromb Haemost. 2006;96(1):3-6.]Search in Google Scholar
[25. Camilleri RS, Cohen H, Mackie IJ, et al. Prevalence of the ADAMTS-13 missense mutation R1060W in late onset adult thrombotic thrombocytopenic purpura. J Thromb Haemost. 2008;6(2):331-338.10.1111/j.1538-7836.2008.02846.x]Search in Google Scholar
[26. Takimoto T, Nakao M, Nakajo T, et al. Acute myocardial infarction as the initial thrombotic event of thrombotic thrombocytopenic purpura. Blood Coagul Fibrinolysis. 2016 Jan 11. [Epub ahead of print]10.1097/MBC.000000000000051326757016]Search in Google Scholar
[27. Yamamoto K, Hattori Y, Shimada K, et al. Sudden death associated with myocardial damage caused by microthrombi in a patient with thrombotic thrombocytopenic purpura. Rinsho Ketsueki. 2015;56(11):2336-40. ]Search in Google Scholar
[28. Duffy SM, Coyle TE. Platelet transfusions and bleeding complications associated with plasma exchange catheter placement in patients with presumed thrombotic thrombocytopenic purpura. J Clin Apher. 2013;28(5):356-8..10.1002/jca.2127923720092]Search in Google Scholar
[29. Blombery P, Scully M. Management of thrombotic thrombocytopenic purpura: current perspectives. J Blood Med. 2014;5:15-23.]Search in Google Scholar
[30. Shelat SG, Ai J, Zheng XL. Molecular biology of ADAMTS13 and diagnostic utility of ADAMTS13 proteolytic activity and inhibitor assays. Semin Thromb Hemost. 2005;31(6):659-72.10.1055/s-2005-925472257722216388417]Search in Google Scholar
[31. Franchini M, Mannucci PM. Advantages and limits of ADAMTS13 testing in thrombotic thrombocytopenic purpura. Blood Transfus. 2008;6(3):127-35.]Search in Google Scholar
[32. Kokame K, Nobe Y, Kokubo Y, et al. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol. Br J Haematol. 2005;129(1):93-100.10.1111/j.1365-2141.2005.05420.x15801961]Search in Google Scholar
[33. Gerritsen HE, Turecek PL, Schwarz HP, et al. Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP) Thromb Haemost. Thromb Haemost. 1999;82(5):1386-9.10.1055/s-0037-1614780]Search in Google Scholar
[34. Rick ME, Moll S, Taylor MA, et al. Clinical use of a rapid collagen binding assay for von Willebrand factor cleaving protease in patients with thrombotic thrombocytopenic purpura. Thromb Haemost. Thromb Haemost. 2002;88(4):598-604.]Search in Google Scholar
[35. Bohm M, Vigh T, Scharrer I. Evaluation and clinical application of a new method for measuring activity of von Willebrand factor-cleaving metalloprotease (ADAMTS13) Ann Hematol. Ann Hematol. 2002;81(8):430-5.10.1007/s00277-002-0502-312223999]Search in Google Scholar
[36. Whitelock JL, Nolasco L, Bernardo A, et al. ADAMTS-13 activity in plasma is rapidly measured by a new ELISA method that uses recombinant VWF-A2 domain as substrate. J Thromb Haemost. 2004;2(3):485-91.10.1111/j.1538-7836.2004.00601.x15009467]Search in Google Scholar
[37. Rieger M, Mannucce P, Kremer Hovinga JA, et al. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood. Blood. 2005;106(4):1262-7.10.1182/blood-2004-11-449015890682]Search in Google Scholar
[38. Petrović D, Čanović P, Mijailović Ž, Popovska-Jovičić B, Jaćović S. Hemolitičko-uremijski sindrom: etiopatogeneza, dijagnostika i osnovni principi lečenja. Med Čas 2015; 49(2):(in print).]Search in Google Scholar
[39. Diaz-Cremades J, Fernandez-Fuertes F, Ruano JA et al. Concurrent thrombotic thrombocytopenic purpura and antiphospholipid syndrome: a rare and severe clinical combination. Br J Haematol. 2009;147(4):584-5.10.1111/j.1365-2141.2009.07856.x19694716]Search in Google Scholar
[40. Ahmed I, Majeed A, Powell R. Heparin induced thrombocytopenia: diagnosis and management update. Postgrad Med J. 2007;83(983):575-82.10.1136/pgmj.2007.059188260001317823223]Search in Google Scholar
[41. McCrae KR. Thrombocytopenia in pregnancy. Hematology Am Soc Hematol Educ Program. 2010; 2010(1):397-402. 10.1182/asheducation-2010.1.39721239825]Search in Google Scholar
[42. Soucemarianadin M, Benhamou Y, Delmas Y, et al. Twice-daily therapeutical plasma exchange-based salvage therapy in severe autoimmune thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. Eur J Haematol. 2015 Nov 26. [Epub ahead of print]10.1111/ejh.1270626608617]Search in Google Scholar
[43. Scully M, Hunt BJ, Benjamin S, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012;158(3):323-35.10.1111/j.1365-2141.2012.09167.x22624596]Search in Google Scholar
[44. Balduini CL, Gugliotta L, Luppi M, et al; Italian TTP Study Group. High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study. Ann Hematol. 2010;89(6):591-596.10.1007/s00277-009-0877-520033409]Search in Google Scholar
[45. Scully M, McDonald V, Cavenagh J, et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood. 2011;118(7):1746-1753.10.1182/blood-2011-03-34113121636861]Search in Google Scholar
[46. Froissart A, Buffet M, Veyradier A, et al. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Crit Care Med. 2012;40(1):104-11.10.1097/CCM.0b013e31822e9d6621926591]Search in Google Scholar
[47. Scully M, Cohen H, Cavenagh J, et al. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol. 2007;136(3):451-61.10.1111/j.1365-2141.2006.06448.x17233847]Search in Google Scholar
[48. Jasti S, Coyle T, Gentile T, et al. Rituximab as an adjunct to plasma exchange in TTP: a report of 12 cases and review of literature. J Clin Apher. 2008;23(5):151-6.10.1002/jca.2017218712712]Search in Google Scholar
[49. Ling HT, Field JJ, Blinder MA. Sustained response with rituximab in patients with thrombotic thrombocytopenic purpura: a report of 13 cases and review of the literature. Am J Hematol. 2009;84(7):418-21.10.1002/ajh.2143919507208]Search in Google Scholar
[50. Chemnitz JM, Uener J, Hallek M, Scheid C. Long-term follow-up of idiopathic thrombotic thrombocytopenic purpura treated with rituximab. Ann Hematol. 2010;89(10):1029-33. 10.1007/s00277-010-0968-320422413]Search in Google Scholar
[51. de la Rubia J, Moscardo F, Gomez MJ, et al. Efficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: results of a Spanish multicenter study. Transfus Apher Sci. 2010;43(3):299-303.10.1016/j.transci.2010.09.01820934383]Search in Google Scholar
[52. Goyal J, Adamski J, Lima JL, Marques MB. Relapses of thrombotic thrombocytopenic purpura after treatment with rituximab. J Clin Apher. 2013;28(6):390-4.10.1002/jca.2128923857472]Search in Google Scholar
[53. Yates S, Matevosyan K, Rutherford C, et al. Bortezomib for chronic relapsing thrombotic thrombocytopenic purpura: a case report. Transfusion. 2014;54(8):2064-7.10.1111/trf.1261424655327]Search in Google Scholar
[54. Shortt J, Oh DH, Opat SS. ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura. N Engl J Med. 2013;368(1):90-2.10.1056/NEJMc121320623281998]Search in Google Scholar
[55. Patel PP, Becker J, Freyer C, et al. Rituximab-refractory thrombotic thrombocytopenic purpura responsive to intravenous but not subcutaneous bortezomib. Transfusion. 2016 Jan 18. [Epub ahead of print]10.1111/trf.1346526779871]Search in Google Scholar
[56. Hie M, Gay J, Galicier L, et al. Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura. Blood. 2014;124(2):204-10.10.1182/blood-2014-01-55024424869941]Search in Google Scholar
[57. Westwood JP, Webster H, McGuckin S, et al. Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse. J Thromb Haemost. 2013;11(3):481-90.10.1111/jth.1211423279219]Search in Google Scholar
[58. Plaimauer B, Kremer Hovinga JA, Juno C, et al. Recombinant ADAMTS13 normalizes von Willebrand factorcleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies. J Thromb Haemost. 2011;9(5):936-944.10.1111/j.1538-7836.2011.04224.x21294825]Search in Google Scholar
[59. Callewaert F, Roodt J, Ulrichts H, et al. Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura. Blood. 2012;120(17): 3603-3610.10.1182/blood-2012-04-42094322948047]Search in Google Scholar
[60. Ulrichts H, Silence K, Schoolmeester A, et al. Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs. Blood. 2011;118(3):757-765. 10.1182/blood-2010-11-31785921576702]Search in Google Scholar